BDM31343
BDM31343 is an Ethionamide (HY-B0276) synergist. BDM31343 inhibits the transcriptional repressor EthR in Mycobacterium tuberculosis, thereby relieving the inhibition of the EthA activator by Ethionamide, and enhancing the efficacy of Ethionamide. BDM31343 effectively inhibits the binding of EthR to DNA, with its IC₅₀ being 3.3 μM. BDM31343 can be used in the research of anti-Mycobacterium tuberculosis.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 1001468-07-0
- Formule: C14H14N4O2S
- Masse moléculaire:302.35
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Voir tous les produits spécifiques à Isoform DNA/RNA Synthesis
More
Activité biologique
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| RAW264.7 | EC50 |
1.5 μM
Compound: 1, BDM31343
|
Inhibition of EthR in Mycobacterium tuberculosis H37Rv expressing GFP infected in mouse RAW264.7 cells assessed as concentration required to ethionamide-induced 50% inhibition of bacterial growth after 5 days by microscopic analysis
Inhibition of EthR in Mycobacterium tuberculosis H37Rv expressing GFP infected in mouse RAW264.7 cells assessed as concentration required to ethionamide-induced 50% inhibition of bacterial growth after 5 days by microscopic analysis
|
[PMID: 21417236] |
Chemical Information
-
CAS No. 1001468-07-0
-
Masse moléculaire 302.35
-
Formule C14H14N4O2S
-
SMILES
N#CCC(N1CCC(CC1)C2=NC(C3=CC=CS3)=NO2)=O
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
[1]. Willand N, et al. Synthetic EthR inhibitors boost antituberculous activity of ethionamide. Nat Med. 2009 May;15(5):537-44. [Content Brief]
[2]. Engohang-Ndong J. Antimycobacterial drugs currently in Phase II clinical trials and preclinical phase for tuberculosis treatment. Expert Opin Investig Drugs. 2012 Dec;21(12):1789-800. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
BDM31343 Related Classifications
HY-165540 Related Classifications
Powered by Bioz